Search Results

 

You need to login or register to view this content

All our reports and results are available free of charge personal use, and/or non-commercial use, however, you must first register with us to view our data.

View full Terms and Conditions



Log In

Respondent CDP 2007: Pfizer Inc.

General Introduction
<>If like introduction answers enter
NOTE CDP response submitted Word / pdf document attached introduction section possible data inputted online response does match question left box blank check response Word / pdf complete answer company **************Environmental Leadership Climate ChangeAs pharmaceutical company advancement good health occurs innovation production distribution medicines preservation healthy environment Pfizer’ s Climate Change Energy Program seeks minimize cost operational restrictions arising carbon constrained environment reduce Pfizer’ s contribution GHG emissions facilitate Pfizer business operational adaptation physical changes resulting warming global climate Pfizer company standard requiring conservation energy reduction greenhouse gases 1996 2002 Pfizer charter member USEPA Climate Leaders Program United States Environmental Protection Agency industry partnership works companies develop long term comprehensive climate change strategies Climate Leaders set aggressive corporate wide GHG reduction goals inventory GHG emissions track progress goals Climate Leader established company wide goal reducing CO2 emissions 35% million dollars sales end 2007 baseline year 2000 2003 expanded goal include commitment meet 35% electricity needs 2010 use clean energy technologies (e g wind power solar power generation) detailed GHG emission inventory established following widely accepted World Resources Institute/World Business Council Sustainable Development Greenhouse Gas Protocol Pfizer’ s Climate Change Energy Program seeks reduce Pfizer’ s contribution GHG emissions minimize cost operational restrictions arising carbon constrained environment Pfizer’ s Global Energy Team plays important role achieving reductions Pfizer’ s energy demand coordination support implementation business level goals [specific examples detailed responses] Reduction GHG emissions comes conservation energy outlined shift clean energy use energy supply Pfizer significant clean energy projects help achieve clean energy procurement goal 35% electricity needs 2010 use clean energy technologies [specific examples detailed responses] addition undertaking clean energy projects Pfizer seeking ways minimize demands non renewable fossil fuel resources example designed new steam boiler Thane India manufacturing plant burns sugar cane briquettes generate steam heating process use evaluating use wood pellets fuel boiler Freiberg Germany manufacturing plant Pfizer moving reducing GHG emissions facility operations working reduce impacts nearly 27 000 automobiles North America Europe Pfizer’ s fleet sales vehicles represents approximately 10% CO2 emissions [specific examples detailed responses] Effectively managing financial implications opportunities associated energy reductions gleaned conservation clean energy projects important component program piloting projects secure preserve carbon credits (e g Energy Efficiency Credits Renewable Energy Credits) preparation emissions trading programs 2006 companies successfully generate trade energy efficiency credits state Connecticut longer term program seeks identify operating risks business opportunities presented changing global climate working closely Pfizer businesses plan operational risks presented severe storm events water availability evaluating role world’ s leading health care company response implications changing disease patterns associated changing global climate Pfizer health care company committed health patients serves broader health world community demonstrated holistic approach taking curb impact global climate change

Download attachment
 
Section A – 1 Climate Change Risks, Opportunities and Strategy
Question 1(a)(i) – Regulatory risks
<>For question state time period possible associated financial implications commercial risks does climate change present company including regulatory risks associated current and/or expected government policy climate change e g emissions limits energy efficiency standards
Currently mandatory regulation applicable Pfizer operations European Union Emission Trading Scheme (EU ETS) Pfizer facilities Europe affected Scheme energy conservation efforts new entrant allowances Pfizer excess allocation sold market place kept future facility expansion Pfizer experienced major direct impact Phase EU ETS higher energy costs partially attributed uncertainty new market seen Future regulations mandatory scheme include incentives businesses reduce energy use current design EU ETS scheme example does provide credit early reduction emissions credit energy efficiency indirect emissions CO2 characteristics baseline set recently credit indirect emissions risks industry investment higher efficiency cogeneration demand opportunities effort understand capture global advantage Pfizer’ s Global Climate Change Energy Team tracking salient legislative proposals applicable landmark court decisions subsequent regulatory directive pertinent issues summaries internal stakeholders order best position Company carbon constrained environment

 
<>Would like provide additional information relating question provided
 Yes 
energy costs typically represent percent pharmaceutical company’ s cost goods percent revenue (refer response Question 4d) Pfizer long standing commitment energy efficiency conservation Pfizer internal standard Energy Conservation 1996 standard applies globally manufacturing research development large offices distribution centers sets performance expectations minimize use fossil fuels reduce greenhouse gas emissions related operations

 
Question 1(a)(ii) Physical risks
<>For question state time period possible associated financial implications commercial risks does climate change present company including physical risks business operations scenarios identified Intergovernmental Panel climate Change expert bodies sea level rise extreme weather events resource shortages
pharmaceutical company develop manufacture product direct impact global climate change impacts indirect (i e climate impact results research manufacture transport sale Pfizer product market) Pfizer long standing global program promote energy conservation increase energy efficiency longer term climate change strategy Pfizer continuing examine potential impact climate change adverse weather patterns operations including stand facilities supply chain management logistics respect supply chain management logistics Pfizer sourcing products party manufacturers Adverse weather events potentially disrupt logistics material effect Pfizer’ s ability deliver medicines markets respect Pfizer’ s stand production research facilities located low lying areas water locations excellent emergency preparedness plans facilities currently face flooding risks locations reviewed light changing weather patterns necessary review facilities include detailed modelling potential flood hazards

 
<>Would like provide additional information relating question provided
 No 

 
Question 1(a)(iii) risks
<>For question state time period possible associated financial implications Apart regulatory physical risks described answers questions 1(a)(i) 1(a)(ii) commercial risks does climate change present company including shifts consumer attitude demand
N/A

 
<>Would like provide additional information relating question provided
 No 

 
Question 1(b) Opportunities
<>For question state time period possible associated financial implications commercial opportunities does climate change present company existing new products services
global leader health care Pfizer positioned address potential human health impacts anticipated changing global climate Similarly Pfizer’ s Animal Health business stands ready address climate related impacts livestock animals

 
<>Would like provide additional information relating question provided
 No 

 
Question 1(c) Strategy
<>For question state time period possible associated financial implications objectives targets strategies undertaken planning manage risks opportunities detailed questions 1(a) 1(b) include adaptation physical risks
Pfizer’ s Climate Change Energy Program seeks minimize cost operational restrictions arising carbon constrained environment reduce Pfizer’ s contribution GHG emissions facilitate Pfizer business operational adaptation physical changes resulting warming global climate Pfizer established Global Energy Team coordinate efforts reduce energy consumption energy costs efficiently meet voluntary 2007 public commitment USEPA Climate Leaders Program partner reduce carbon dioxide emissions 35 percent million dollars sales (from 2000 baseline) support aggressive goal Pfizer implemented approximately 1130 energy projects 2000 2006 achieving reduction approximately 235 000 MTs CO2 Additionally Pfizer set public goal 2010 supply 35 percent global energy needs cleaner sources efforts achieve clean energy goal December 2006 Pfizer implemented 9 clean energy projects sites world additional 15 projects planning feasibility stage development projects range combined heat power plants photovoltaic systems wind turbines Pfizer Green Building Team contributing holistic fashion integration energy environmental responsible practices capital projects building operations striving realize 80% Green Building potential capital projects greater $1 Million scored Pfizer green building evaluation tool Additionally 12 keys principles Pfizer’ s Green Chemistry (GC) program design processes inherently energy resource efficient Green Chemistry initiative achieved demonstrated results recognition 2002 prestigious awards given Pfizer learn Green Chemistry initiative Pfizer EHS web site http //www pfizer com/ehs/initiatives/green_chemistry html Collectively proactive voluntary measures strengthened strong culture energy conservation preparedness carbon constrained economy anticipate continued effective implementation worldwide energy program limit potentially adverse economic impact climate change Pfizer expect seen increase cost energy result supply constraints tax levies environmental restrictions related fuel switching prefer view market impacts opportunities advance demand management projects lamping projects HVAC upgrades cogeneration projects

 
<>Would like provide additional information relating question provided
 No 

 
Section A – 2 Greenhouse Gas Emissions Accounting
Question 2(a)(i) – Methodology – Accounting Year
<>Please state accounting year used report GHG emissions
Financial accounting year 31 December 2006

 
<>Would like provide additional information relating question provided
 No 

 
Question 2(a)(ii) – Methodology
<>Please state methodology emissions calculated
 GHG Protocol 

 
<>Please provide additional information
Pfizer calculations GHG emissions completed referencing WRI GHG Protocol using Operational Control Organizational Boundary method materiality threshold 5% data based facility specific utility invoices purchased quantities electricity fuel oil natural gas steam

 
<>Please state reporting boundaries data provided questionnaire
Option 1 – consolidated financial statements

 
<>Please provide additional information

 
<>Would like provide additional information relating question provided
 No 

 
Question 2(a)(iii) – Methodology – External verficiation
<>Please state information provided externally verified audited
 Yes 
Pfizer member USEPA Climate Leaders program member Climate Leaders partnership minimum Pfizer required 1 Set aggressive corporate wide greenhouse gas (GHG) emissions reduction goal achieved 10 years 2 Perform corporate wide inventory major greenhouse gases (CO2 CH4 N2O HFCs PFCs SF6) completed building inventory step calculating emission reduction goal data collected quality assured external consultant inventory revealed CO2 principal GHG 3 Report annually inventory data USEPA document progress reduction goal USEPA independently verifies data report program participants measures progress achieving reduction target reporting obligations accordance WRI GHG Protocol USEPA Climate Leaders requirements requirements captured Pfizer’ s Inventory Management Plan Pfizer’ s written procedure collecting reporting GHG emissions information Climate Leaders partnership www epa gov/climateleaders

 
<>Would like provide additional information relating question provided
 No 

 
Question 2(a)(iv) – Methodology – Variations emissions
<>Please provide explanation significant variations emissions year year major acquisitions divestments introduction new technologies
Pfizer sold Consumer Health Division December 2006 emissions sites associated transaction included inventory reported Consumer business accounted approximately 70 000 MT (2 7 %) total CO2eq emissions 2006 using 2005 footprint facilities contributed additional reductions 2 000 tCO2eq 9 000 MWh conservation project implementation 2006 2006 Pfizer achieved absolute energy reduction 517 000 MWh (6 5% including fleet) GHG emissions reduction 179 400 tCO2e (6 9%) portion reduction attributed decreased production facilities large direct result conservation project implementation

 
<>Would like provide additional information relating question provided
 No 

 
Question 2(b) – Scope 1 Scope 2 GHG Protocol Year 1 answers
state direct indirect GHG emissions metric tonnes CO2e global Annex B countries having difficulty reporting emissions figures CO2e metric tonnes guidance answering CDP5 questionnaire available
<>Please enter accounting year used report GHG emissions details
31 December 2006

 
<>Total Global Emissions
<>2408317 CO2e metric tonnes

 
<>Total Emissions Annex B countries
<>1948187 CO2e metric tonnes

 
<>Scope 1 activity emissions globally
<>1223876 CO2e metric tonnes

 
<>Scope 1 activity emissions Annex B
<>870685 CO2e metric tonnes

 
<>Scope 2 activity emissions globally
<>1184441 CO2e metric tonnes

 
<>Scope 2 activity emissions Annex B
<>1077502 CO2e metric tonnes

 
<>Please state MWh electricity purchased consumed company globally
2041190 MWh

 
<>Please state MWh electricity purchased consumed company Annex B countries
1856100 MWh

 
<>Please state percentage purchased consumed MWh electricity renewables globally
7 %

 
<>Please state percentage purchased consumed MWh electricity renewables Annex B countries
6 %

 
<>Would like provide additional information relating question provided
 Yes 
Country provided request

 
Question 2(c) – Scope 3 GHG Protocol Year 1 answers
<>Please enter accounting year used report GHG emissions details
31 December 2006

 
<>If possible provide estimates metric tonnes CO2e following categories emissions Use/disposal company’ s products services
<>Prior new product reaching market place Pfizer uses multi disciplinary approach evaluate environmental health safety (EHS) profile interdisciplinary team manufacturing research development experts including chemists engineers EHS staff evaluate new production processes objective understanding responding potential environmental impacts including energy use minimizing use hazardous substances minimizing process waste maximizing process yield safety manufacturing process engineers EHS professional partner improve process efficiencies things reducing energy requirements related CO2 emissions Pfizer aggressively working reduce plastic paper packaging use Environmental professionals actively collaborating packaging procurement colleagues identify eliminate unnecessary packaging Reductions paper plastic requirements business direct impact scope emissions 2006 Pfizer built plastics reduction benefits calculator assist quantifying environmental energy savings opportunities associated packaging improvements currently pilot programs underway track savings reductions anticipated plastics reduction benefits calculator support business cases future packaging reduction projects

 
<>Your supply chain
<>Pfizer initiating effort understand companies doing regard GHG emissions direct supply chain partners hope benchmark activities research practices broadly recommend path forward address company stakeholder needs area working indirect suppliers improve purchasing practices minimize cost environmental impacts product service purchasing decisions

 
<>External distribution/logisitics
<>Looking downstream logistics distribution services continuing evaluate effect overall emissions profile impact emissions determined significant (> 5% total emissions) included inventory parallel Pfizer exploring options measure improve impact logistics operations currently reviewing participation USEPA’ s SmartWay® Program SmartWay® Transport Partnership innovative collaboration U S EPA freight industry increase energy efficiency significantly reducing greenhouse gases air pollution

 
<>Employee business travel
<>In 2004 Pfizer completed comprehensive analysis footprint resulting business travel evaluation concluded GHG emissions associated business travel estimated 231 000 MT CO2 221 579 air 7 654 auto 1 546 rail represents approximately 8 percent Pfizer’ s total carbon dioxide emissions year information used current projects address scope 3 emission improvement opportunities

 
<>Other

 
<>Please provide details sources emissions entered figure "Other" box

 
<>Please provide information measurement scope 3 emissions

 
<>Would like provide additional information relating question provided
 No 

 
Section B – 3 Additional Greenhouse Gas Emissions Accounting
Question 3(a) – Scope 1 Scope 2 GHG Protocol emissions country
Using methodology set 2(a) state emissions country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
<>
Country Scope 1
Emissions (Tonnes CO2e)
Scope 2
Emissions (Tonnes CO2e)

Download attachment
 
<>Would like provide additional information relating question provided
 No 

 
Question 3(b) – Facilities covered EU Emissions Trading Scheme
provide details total emissions metric tonnes CO2e facilities covered EU ETS details allowances issued applicable National Allocation Plans
<>Emissions total facilities covered EU ETS figure metric tonnes CO2e

 
<>Total number allowances issued National Allocation Plans applicable installations covered EU ETS

Download attachment
 
<>Would like provide additional information relating question provided

 
Question 3(c) – EU ETS impact
<>What impact profitability EU Emissions Trading Scheme
end 2006 Pfizer transferred small allocation surplus Ireland Sandwich United Kingdom address allocation shortfall Sandwich facility current prediction close operating allocation end year period (2005– 2007) Phase 1 EUETS Pfizer engaged purchase sale emission units EUETS seen increase European facilities increased electricity prices associated EUETS passed electricity providers Pfizer

 
<>Would like provide additional information relating question provided

 
Section B – 4 Greenhouse Gas Emissions Management
Question 4(a)(i) Reduction programmes
emission reduction programs does company place include reduction programs related operations energy consumption supply chain product use/disposal
<>Does company emissions reduction program
 Yes 

 
<>What baseline year emissions reduction program (YYYY format 1990)
2000

 
<>If use baseline year reduction programme provide details reference point programme

 
<>Would like provide additional information relating question provided

 
Question 4(a)(ii) Reduction programmes
emissions reduction targets period targets extend
<>Emissions reductions target (%)
35 %

 
<>Time frame reduction target
2007

 
<>Further information
Pfizer set public goals Reduce CO2 emissions 35% $ million sales 2007 baseline year 2000 Pfizer set goal participation EPA Climate Leaders Partnership Meet 35% Pfizer’ s electricity needs 2010 use "clean" energy technologies Clean energy sources defined wind solar biomass hydro cogeneration strategy achieving goals Implement energy conservation projects Pfizer facilities worldwide Increase use clean energy sources Leveraging voluntary markets renewable energy energy efficiency provide incentives additional investment energy conservation

 
<>Would like provide additional information relating question provided

 
Question 4(a)(iii) Reduction programmes
<>What investment been/will required achieve targets (In $)
50000000 US$

 
<>Over time period (In years)
6

 
<>More
Pfizer implemented approximately 1 130 energy conservation projects 2000 2006 projects required capital investment approximately $50 million

 
<>Would like provide additional information relating question provided

 
Question 4(a)(iv) Reduction programmes
<>What emissions reductions associated costs savings achieved date result program
Pfizer’ s CO2 reduction resulting projects implemented achieve GHG reduction goal total approximately 235 000 MTs CO2 representing approximately $30 million annual savings portion represents recurring annual savings life project efforts achieve goal Pfizer implemented 9 clean energy projects sites world additional 15 projects planning feasibility stage development projects range combined heat power plants photovoltaic systems wind turbines

 
<>Would like provide additional information relating question provided

 
Question 4(a)(v) Reduction programmes
<>What renewable energy energy efficiency activities undertaking manage emissions
second energy goal meet 35% Pfizer’ s electricity needs 2010 use "clean" energy technologies (i e wind solar biomass hydro cogeneration) defines program elements minimize use fossil fuels non renewable limited natural resource process reduce GHG emissions related facility activities Examples stated response Question 2iv Pfizer achieved absolute energy reduction approximately 6 5% GHG emissions reduction 6 9% portion reduction attributed decreased production facilities large direct result conservation project implementation Nagoya Japan (PGM) registered 8 000 MWh savings implementing turbine pass project cogeneration plant purchasing electricity grid lower price generated burning fuel oil site benefited reduced fuel consumption (5 000 MWh) site incinerator conservation project implemented 2005 Groton Connecticut (PGRD) implemented equipment upgrades initiatives lighting retrofits waste heat recovery led energy emissions reductions 12 000 MWh 4 400 tCO2 respectively saving $1 million Kalamazoo Michigan (PGM) benefited implemented conservation projects site completed 21 projects 2006 resulting 30 000 MWh savings projects led $751 000 recurring dollar savings reduction 10 200 tCO2 Projects varied optimizing site operations consolidating operations lighting compressed air water initiatives Likewise facilities world Brooklyn New York (PGM) Barceloneta Puerto Rico PGM) Loughbeg DP Ireland (PGM) achieved reductions operational changes conservation initiatives Regional energy teams reported 417 conservation projects completed 2006 leading energy emissions savings 206 000 MWh 69 000 tCO2 respectively generating recurring savings $13 million Including going savings projects completed years prior 2006 increases reductions 563 000 MWh 180 000 tCO2 $32 million energy conservation efforts reduce impact fleet reduce cost burden uncertainty associated fuel price volatility Pfizer’ s Fleet Management organization embarked pilot programs past years Pfizer tested hybrid Toyota Prius vehicles fuel efficiency ease use practicality small size Pfizer expanded pilot hybrid 50 Toyota Camry hybrids distributed Sales Force year – fuel efficiency vehicle applicability evaluated different territories driving conditions terrains Approximately 1 600 Chevrolet Impala bi fuel vehicles purchased Pfizer incremental cost company – vehicles use E 85 (an ethanol blend) regular gasoline interchangeably

 
<>Would like provide additional information relating question provided

 
Question 4(b) Emissions trading
company’ s strategy trading EU Emissions Trading Scheme CDM/JI projects trading systems (e g CCX RGGI etc) relevant Explain involvement following
<>EU ETS
Pfizer’ s strategy regard trading carbon preparedness year phase 1 period EUETS believe operate allocation likely need purchase addition carbon credits Pfizer believes future regulations mandatory scheme include incentives businesses reduce energy use current design EU ETS scheme example does provide credit early reduction emissions credit energy efficiency indirect emissions CO2 characteristics baseline set recently credit indirect emissions disincentive industry investment higher efficiency cogeneration demand opportunities

 
<>CDM/JI
explored CDM projects evaluated CDM/JI process feasibility perspective event want explore future opportunities area piloting projects secure preserve carbon credits (e g Energy Efficiency Credits Renewable Energy Credits) preparation emissions trading programs 2006 companies successfully generate trade energy efficiency credits state Connecticut voluntary market project undertaken demonstrate ability preparedness transactions type researched developed strategies address financial CO2 accounting associated reporting carbon transactions

 
<>CCX
continue review evaluation Climate Leaders CCX California Climate Registry DOE 1605B Program determine best way position Pfizer regard early action credits Likewise closely monitoring development tracking accounting mechanisms Climate Registry United States seeking manage activities manner position Pfizer carbon constrained regulated economy Pfizer supports recent endorsement Connecticut Registry publicly stated [“ Pfizer supports Connecticut members Climate Registry leadership establishing common greenhouse gas emissions reporting provide uniform transparent registry verify early actions reduce greenhouse gases ” ]http //www theclimateregistry org/

 
<>RGGI

 
<>Others

 
<>More

 
<>Would like provide additional information relating question provided

 
Question 4(c) Emissions intensity
state measurement believe best describes company’ s emissions intensity performance historical current emissions intensity measurements targets
<>Best measurement emissions intensity company
Emissions intensity ratio carbon dioxide emissions measure economic output establishing 2007 GHG reduction goal Pfizer used revenue measure emissions intensity (MT/$M US) product output homogeneous respect commodity based businesses (e g utilities petroleum products allied metals) Dollars revenue common thread Pfizer activities considered relevant terms state target

 
<>Historical intensity details

 
<>Current intensity details

 
<>Target details

 
<>Would like provide additional information relating question provided

 
Question 4(d) Energy costs
total costs energy consumption e g fossil fuels electric power percentage total operating costs does represent
<>Total costs energy consumption (in US$)
333906419 US$

 
<>Percentage total operating costs (%)

 
<>More Details
NOTE CDP complete list page 14 attached pdf

 
<>Would like provide additional information relating question provided

 
Question 4(e) Planning
estimate company’ s future emissions provide details estimates summarize methodology factor cost future emissions capital expenditure planning considerations impact investment decisions
<>Do estimate company’ s future emissions
 Yes 

 
<>Please provide details estimates summarize methodology provide details estimate company's future emissions
developing strategy second generation GHG reduction goal (Pfizer’ s current goal expires end 2007) detailed analysis underway project future emissions based variety factors performing analysis considering organic growth decline products marketplace time efficiencies expected achieved energy conservation efforts outsourcing changes fleet aviation strategies EEC REC markets implementation clean energy projects evaluation ongoing completed end 2007 time Pfizer commit second generation energy goal recognizing environmental benefits economic savings Pfizer continues factor cost future emissions capital expenditure planning Green Building Team working Pfizer’ s finance organization developed lifecycle cost tool help properly quantify cost value implementing green building enhancements capital spending continue evolve tool advance initiatives adequately capture dynamics energy climate space capital processes Example 2006 Pfizer able advance photovoltaic project La Jolla site using Pfizer Green Building Global Operations Equipment Lifecycle Investment Analysis Model capital expenditure process Specifically tool afforded engineering opportunity evaluate critical factors energy rebates tax credits exemptions accelerated depreciation lifetime earnings equipment ultimately exact return investment

 
<>How factor cost future emissions capital expenditure planning

 
<>Have considerations impact investment decisions

 
<>Please provide details

 
<>Would like provide additional information relating question provided

 
Section B – 5 Climate Change Governance - Responsibility
Question 5(a)(i) Responsibility
<>Which Board Committee executive body overall responsibility climate change
Environment health safety (EHS) management included responsibilities Audit Committee Board Pfizer’ s General Counsel chairman Company’ s EHS Steering Committee capacity reports Audit Committee EHS performance

 
<>Would like provide additional information relating question provided

 
Question 5(a)(ii) Responsibility
<>What mechanism Board executive body reviews company’ s progress status regarding climate change
EHS Steering Committee provides strategic policy direction EHS matters including climate change broad support initiatives improve EHS performance includes members senior Pfizer management Pfizer Global Research Development Science Technology Global Manufacturing Global Compliance

 
<>Would like provide additional information relating question provided

 
Question 5(b) Individual performance
<>Do provide incentive mechanisms managers reference activities relating climate change strategy including attainment GHG targets

 
<>If provide details
Day day strategic management energy climate change issues responsibility Director Climate Change Energy Pfizer Global Environment Health Safety Pfizer facilities support guidance corporate business based technical experts responsible implementing performance expectations Pfizer Energy Guideline information Pfizer’ s EHS management structure roles responsibilities visit internet site http //www pfizer com/ehs/mgmt/governance html respect communications Climate Change Energy Program publicly report global energy program related public company wide goals www pfizer com/ehs Additionally partner engaged dialogue climate change energy issues number external governmental non governmental organizations including USEPA Climate Leaders WRI Climate Northeast Business Roundtable Climate Resolve Climate Registry Climate Group Pfizer embraces Environmental Principles Global Compact Pfizer joined 2002 reports externally Communication Progress (COP) mechanism annual progress date EHS participated United Nations Framework Convention Climate Change (UNFCCC) Conference Parties Convention (COP11)/ Meeting Parties (MOP) met parallel Montreal (Nov Dec 2005) member industry panel voluntary GHG emission reduction programs recent April 2007 Pfizer recognized Climate Group New York City’ s leaders carbon footprint reduction energy conservation achievements http //www theclimategroup org/

 
<>Would like provide additional information relating question provided

 
General Information
<>Please add general information attachments related specific question like include response

 
We have upgraded our website login. If you have registered to view CDP responses before December 23, please re-register and we will issue new login details.
  Join the CDP LinkedIn group Follow @cdp on Twitter          Subscribe to receive our monthly newsletter
  Connect with us          Newsletter
   
 
 
  © 2014 CARBON DISCLOSURE PROJECT, Registered Charity no. 1122330.
A company limited by guarantee registered in England no. 05013650